Beximco Pharmaceuticals Limited
BXP.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | £25,872,069 | £21,827,629 | £35,817,231 | £45,019,776 |
| - Cash | £854,106 | £1,135,686 | £1,168,674 | £675,467 |
| + Debt | £6,025,431 | £10,611,899 | £12,370,702 | £7,631,304 |
| Enterprise Value | £31,043,394 | £31,303,842 | £47,019,259 | £51,975,614 |
| Revenue | £44,391,604 | £39,266,662 | £34,669,172 | £29,493,574 |
| % Growth | 13.1% | 13.3% | 17.5% | – |
| Gross Profit | £19,633,987 | £17,102,229 | £15,814,252 | £13,923,502 |
| % Margin | 44.2% | 43.6% | 45.6% | 47.2% |
| EBITDA | £10,640,325 | £9,370,933 | £8,246,834 | £7,387,386 |
| % Margin | 24% | 23.9% | 23.8% | 25% |
| Net Income | £5,829,529 | £4,614,066 | £5,123,137 | £5,127,694 |
| % Margin | 13.1% | 11.8% | 14.8% | 17.4% |
| EPS Diluted | 13.07 | 10.34 | 11.48 | 11.49 |
| % Growth | 26.4% | -9.9% | -0.1% | – |
| Operating Cash Flow | £8,364,466 | £6,084,787 | £5,493,375 | £6,023,264 |
| Capital Expenditures | -£2,234,557 | -£2,710,028 | -£2,939,498 | -£2,558,418 |
| Free Cash Flow | £6,129,909 | £3,374,759 | £2,553,877 | £3,464,846 |